Evidence map›Paper›PMID 33933705›Full record

ArticleJournal of pharmaceutical and biomedical analysis2021

High-Performance affinity chromatographic studies of repaglinide and nateglinide interactions with normal and glyoxal- or methylglyoxal-modified human albumin serum.

Susan T Ovbude, Pingyang Tao, Zhao Li, David S Hage

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical and biomedical analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Characterization of binding by sulfonylureas with normal or modified human serum albumin using affinity microcolumns prepared by entrapment.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2023
    Article
  4. Article
  5. Analysis of the binding of warfarin to glyoxal- and methylglyoxal-modified human serum albumin by ultrafast affinity extraction.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2022
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Susan T OvbudeChemistry Department, University of Nebraska, Lincoln, NE, 68588, USA.
Pingyang TaoChemistry Department, University of Nebraska, Lincoln, NE, 68588, USA.
Zhao LiChemistry Department, University of Nebraska, Lincoln, NE, 68588, USA.
David S HageChemistry Department, University of Nebraska, Lincoln, NE, 68588, USA. Electronic address: dhage1@unl.edu.
University of Nebraska–Lincoln · US

Funding

NIDDK NIH HHS R01 DK069629
6 · The paper itself

Abstract

During diabetes human serum albumin (HSA), an important drug transport protein, can be modified by agents such as glyoxal (Go) and methylglyoxal (MGo) to form advanced glycation end-products. High-performance affinity microcolumns and zonal elution competition studies were used to compare interactions by the anti-diabetic drugs repaglinide and nateglinide with normal and Go- or MGo-modified HSA at Sudlow sites I and II of this protein. Both drugs had their strongest binding at Sudlow site II for the normal and modified forms of HSA. The association equilibrium constants at this site for repaglinide and nateglinide with normal HSA were 6.1 (± 0.2) × 10

Indexed as

GlyoxalPyruvaldehydeCarbamatesChromatography, AffinityGlycosylationHumansNateglinidePiperidinesProtein BindingSerum AlbuminSerum Albumin, HumanCarbamatesGlyoxalNateglinidePiperidinesPyruvaldehyderepaglinideSerum AlbuminSerum Albumin, HumanAdvanced glycation end-productsDrug-protein bindingHigh-performance affinity chromatographyHuman serum albuminNateglinideRepaglinide

Identifiers

PMID33933705
PMCPMC8169628
OpenAlexW3157819769

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.